Coevolution study of tau and a-synuclein suggests a connection between their normal interaction in neurons and the Parkinson's disease-associated mutation A53T

Main Article Content

James M Gruschus

Abstract

Alpha-synuclein lies at the center of Parkinson’s disease etiology, and polymorphisms in the gene for the microtubule-associated protein tau are risk factors for getting the disease.  Tau and a-synuclein interact in vitro, and a-synuclein can also compete with tau binding to microtubules.  To test whether these interactions might be part of their natural biological functions, a correlated mutation analysis was performed between tau and a-synuclein, looking for evidence of coevolution.  For comparison, analyses were also performed between tau and b- and g-synuclein.  In addition, analyses were performed between tau and the synuclein proteins and the neuronal tubulin proteins. Potential correlated mutations were detected between tau and a-synuclein, one involving an a-synuclein residue known to interact with tau in vitro, Asn122, and others involving the Parkinson’s disease-associated mutation A53T. No significant correlated mutations were seen between tau and b- and g-synuclein.  Tau showed potential correlated mutations with the neuron-specific bIII-tubulin protein, encoded by the TUBB3 gene.  No convincing correlated mutations were seen between the synuclein and tubulin proteins, with the possible exception of b-synuclein with bIVa-tubulin, encoded by the TUBB4A gene.   While the correlated mutations between tau and a-synuclein suggest the two proteins have coevolved, additional study will be needed to confirm that their interaction is part of their normal biological function in cells.

Keywords: Correlated mutations analysis, mutual information, tauopathy, Alzheimer’s disease, axon, neurodegenerative, intrinsically disordered protein, protein-protein interaction

Article Details

How to Cite
GRUSCHUS, James M. Coevolution study of tau and a-synuclein suggests a connection between their normal interaction in neurons and the Parkinson's disease-associated mutation A53T. Medical Research Archives, [S.l.], v. 9, n. 7, july 2021. ISSN 2375-1924. Available at: <https://esmed.org/MRA/mra/article/view/2497>. Date accessed: 27 may 2024. doi: https://doi.org/10.18103/mra.v9i7.2497.
Section
Research Articles

References

1. Kempster PA, O'Sullivan SS, Holton JL, Revesz T, Lees AJ. Relationships between age and late progression of Parkinson’s disease: a clinico-pathological study. Brain. 2010;133(Pt6):1755-1762. doi:10.1093/brain/awq059

2. Zeng Y, Yang J, Zhang B, Gao M, Su Z, Huang Y. The structure and phase of tau: from monomer to amyloid filament. Cell Mol Life Sci. 2021;78(5):1873-1886. doi:10.1007/s00018-020-03681-x

3. Edwards TL, Scott WK, Almonte C, Burt A, Powell EH, Beecham GW, Wang L, Züchner S, Konidari I, Wang G, Singer C, Nahab F, Scott B, Stajich JM, Pericak-Vance M, Haines J, Vance JM, Martin ER. Genome-wide association study confirms SNPs in SNCA and the MAPT region as common risk factors for Parkinson disease. Ann Hum Genet. 2010;74(2):97-109. doi:10.1111/j.1469-1809.2009.00560.x

4. Siegert A, Rankovic M, Favretto F, et al. Interplay between tau and α-synuclein liquid-liquid phase separation [published online ahead of print, 2021 Jan 15]. Protein Sci. 2021;10.1002/pro.4025. doi:10.1002/pro.4025

5. Carnwath T, Mohammed R, Tsiang D. The direct and indirect effects of α-synuclein on microtubule stability in the pathogenesis of Parkinson's disease. Neuropsychiatr Dis Treat. 2018;14:1685-1695. doi:10.2147/NDT.S166322

6. Kadavath H, Hofele RV, Biernat J, et al. Tau stabilizes microtubules by binding at the interface between tubulin heterodimers. Proc Natl Acad Sci U S A. 2015;112(24):7501-7506. doi:10.1073/pnas.1504081112

7. Melková K, Zapletal V, Narasimhan S, et al. Structure and functions of microtubule associated proteins tau and MAP2c: similarities and differences. Biomolecules. 2019;9(3):105. doi:10.3390/biom9030105

8. Roll-Mecak A. The tubulin code in microtubule dynamics and information encoding. Dev Cell. 2020;54(1):7-20. doi:10.1016/j.devcel.2020.06.008

9. Uhlén M, Fagerberg L, Hallström BM, et al. Proteomics. Tissue-based map of the human proteome. Science. 2015;347(6220):1260419. doi:10.1126/science.1260419

10. Zhang H, Kouadio A, Cartledge D, Godwin AK. Role of gamma-synuclein in microtubule regulation. Exp Cell Res. 2011;317(10):1330-1339. doi:10.1016/j.yexcr.2010.10.013
11. Gruschus, JM. An evolutionary affair – the connection between Gaucher disease and Parkinson's disease. In Synuclein and the Coelacanth – The Molecular and Evolutionary Origins of Parkinson's Disease. Cambridge, MA, Academic Press, 2021:159-179. doi:10.1016/B978-0-323-85707-9.00015-0

12. Gruschus JM. Did α-synuclein and glucocerebrosidase coevolve? Implications for Parkinson's disease. PLoS One. 2015;10(7):e0133863. doi:10.1371/journal.pone.0133863

13. Dunn SD, Wahl LM, Gloor GB. Mutual information without the influence of phylogeny or entropy dramatically improves residue contact prediction. Bioinformatics. 2008;24(3):333-340. doi:10.1093/bioinformatics/btm604

14. Gustke N, Trinczek B, Biernat J, Mandelkow EM, Mandelkow E. Domains of tau protein and interactions with microtubules. Biochemistry. 1994;33(32):9511-9522. doi:10.1021/bi00198a017

15. Alexander JE, Hunt DF, Lee MK, et al. Characterization of posttranslational modifications in neuron-specific class III beta-tubulin by mass spectrometry. Proc Natl Acad Sci U S A. 1991;88(11):4685-4689. doi:10.1073/pnas.88.11.4685

16. Ju JH, Maeng JS, Lee DY, Piszczek G, Gelmann EP, Gruschus JM. Interactions of the acidic domain and SRF interacting motifs with the NKX3.1 homeodomain. Biochemistry. 2009;48(44):10601-10607. doi:10.1021/bi9013374

17. Wu KP, Baum J. Detection of transient interchain interactions in the intrinsically disordered protein alpha-synuclein by NMR paramagnetic relaxation enhancement. J Am Chem Soc. 2010;132(16):5546-5547. doi:10.1021/ja9105495

18. McKibben KM, Rhoades E. Independent tubulin binding and polymerization by the proline-rich region of Tau is regulated by Tau's N-terminal domain. J Biol Chem. 2019;294(50):19381-19394. doi:10.1074/jbc.RA119.010172

19. Kowarsch A, Fuchs A, Frishman D, Pagel P. Correlated mutations: a hallmark of phenotypic amino acid substitutions. PLoS Comput Biol. 2010;6(9):e1000923. doi:10.1371/journal.pcbi.1000923

20. Gruschus, JM. Attack of the oligomers – alpha-synuclein amyloid oligomers and their pathogenic roles. In Synuclein and the Coelacanth – The Molecular and Evolutionary Origins of Parkinson's Disease. Cambridge, MA, Academic Press, 2021:129-158. doi:10.1016/B978-0-323-85707-9.00001-0

21. Kwok JB, Teber ET, Loy C, et al. Tau haplotypes regulate transcription and are associated with Parkinson's disease. Ann Neurol. 2004;55(3):329-334. doi:10.1002/ana.10826

22. Sánchez-Juan P, Moreno S, de Rojas I, et al. The MAPT H1 haplotype is a risk factor for Alzheimer's disease in APOE ε4 non-carriers. Front Aging Neurosci. 2019;11:327. doi:10.3389/fnagi.2019.00327

23. Labbé C, Ogaki K, Lorenzo-Betancor O, et al. Role for the microtubule-associated protein tau variant p.A152T in risk of α-synucleinopathies. Neurology. 2015;85(19):1680-1686. doi:10.1212/WNL.0000000000001946

24. Sydow A, Hochgräfe K, Könen S, et al. Age-dependent neuroinflammation and cognitive decline in a novel Ala152Thr-Tau transgenic mouse model of PSP and AD. Acta Neuropathol Commun. 2016;4:17. doi:10.1186/s40478-016-0281-z